Citizens JMP Reiterates a Buy Rating on CorMedix Inc. (CRMD)

CorMedix Inc. (NASDAQ:CRMD) is one of the best affordable biotech stocks to invest in now. On September 9, Citizens JMP analyst Jason Butler reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and set a price target of $22.00.

Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks?

In other news, CorMedix Inc. announced on September 2 the successful completion of its previously announced acquisition of Melinta Therapeutics LLC. Melinta Therapeutics LLC is a private commercial-stage company that provides innovative therapies for acute and life-threatening illnesses.

Management called the deal “transformational” for the company, expanding and diversifying its commercial product portfolio with “seven innovative drug products and a pipeline expansion indication with near–term revenue growth potential”.

CorMedix Inc. is a medical device and biopharmaceutical company that develops and commercializes therapeutics to treat and prevent diseases and medical conditions.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.